Orthocell (ASX:OCC) said 10 surgeries have taken place in the US using its nerve repair product, Remplir, and it lodged 36 applications to hospital value assessment committees with three approvals already received, according to a Wednesday Australian bourse filing.
The hospitals targeted for value assessment committee approval have been sourced from the firm's network of US distributors.
The company hired two on-the-ground employees in the US, including a regional sales director, per the filing. It also shipped 4,000 Remplir units to its US logistics provider, Uniphar, for use in US surgical procedures.
Orthocell's shares rose nearly 2% in early trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。